NASDAQ:ARAYAccuray Stock Price, Forecast & News

Accuray's stock was trading at $2.27 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ARAY stock has decreased by 8.8% and is now trading at $2.07. View which stocks have been most impacted by Coronavirus.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Accuray in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Accuray.

Accuray is scheduled to release its next quarterly earnings announcement on Thursday, August 20th 2020. View our earnings forecast for Accuray.

Accuray Incorporated (NASDAQ:ARAY) posted its quarterly earnings results on Tuesday, April, 28th. The medical equipment provider reported $0.03 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.04) by $0.07. The medical equipment provider earned $99.55 million during the quarter, compared to analysts' expectations of $96.46 million. Accuray had a negative return on equity of 14.83% and a net margin of 0.64%. View Accuray's earnings history.

4 equities research analysts have issued twelve-month target prices for Accuray's stock. Their forecasts range from $4.00 to $10.00. On average, they expect Accuray's share price to reach $7.00 in the next year. This suggests a possible upside of 238.2% from the stock's current price. View analysts' price targets for Accuray.

Media headlines about ARAY stock have been trending negative this week, InfoTrie Sentiment reports. The research firm rates the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Accuray earned a daily sentiment score of -2.4 on InfoTrie's scale. They also gave news headlines about the medical equipment provider a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the immediate future. View the latest news about Accuray.

Accuray saw a drop in short interest in June. As of June 15th, there was short interest totaling 2,910,000 shares, a drop of 5.8% from the May 31st total of 3,090,000 shares. Based on an average daily volume of 620,700 shares, the days-to-cover ratio is currently 4.7 days. Approximately 3.4% of the company's shares are sold short. View Accuray's Current Options Chain.

Some companies that are related to Accuray include Abbott Laboratories (ABT), Medtronic (MDT), Becton Dickinson and (BDX), Stryker (SYK), Intuitive Surgical (ISRG), Boston Scientific (BSX), Baxter International (BAX), Edwards Lifesciences (EW), DexCom (DXCM), IDEXX Laboratories (IDXX), ResMed (RMD), Teleflex (TFX), Hologic (HOLX), Insulet (PODD) and Steris (STE). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Accuray investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), Activision Blizzard (ATVI), Intel (INTC), Tesla (TSLA), Corbus Pharmaceuticals (CRBP), Netflix (NFLX), Abeona Therapeutics (ABEO), Amarin (AMRN) and AVEO Pharmaceuticals (AVEO).

Accuray trades on the NASDAQ under the ticker symbol "ARAY."

Accuray's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Diversified Trust Co (0.02%). Company insiders that own Accuray stock include Andrew J Kirkpatrick, Jesse Chew, Joseph E Whitters, Joshua Levine, Patrick Spine and Shigeyuki Hamamatsu. View institutional ownership trends for Accuray.

ARAY stock was bought by a variety of institutional investors in the last quarter, including Diversified Trust Co. Company insiders that have bought Accuray stock in the last two years include Joseph E Whitters, and Joshua Levine. View insider buying and selling activity for Accuray.

Shares of ARAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ARAY stock can currently be purchased for approximately $2.07.

Accuray has a market capitalization of $187.37 million and generates $418.79 million in revenue each year. The medical equipment provider earns $-16,430,000.00 in net income (profit) each year or ($0.15) on an earnings per share basis. Accuray employs 998 workers across the globe.

The official website for Accuray is www.accuray.com.

Accuray's mailing address is 1310 CHESAPEAKE TERRACE, SUNNYVALE CA, 94089. The medical equipment provider can be reached via phone at 408-716-4600 or via email at [email protected]